Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2015 Oct 2

PMID 26423407

Citations 33

Authors

R Martin-Iguacel

J M Llibre

N Friis-Moller

Affiliations

Soon will be listed here.

Abstract

With more effective and widespread antiretroviral treatment, the overall incidence of AIDS- or HIV-related death has decreased dramatically. Consequently, as patients are aging, cardiovascular disease (CVD) has emerged as an important cause of morbidity and mortality in the HIV population. The incidence of CVD overall in HIV is relatively low, but it is approximately 1.5-2-fold higher than that seen in age-matched HIV-uninfected individuals. Multiple factors are believed to explain this excess in risk such as overrepresentation of traditional cardiovascular risk factors (particularly smoking), toxicities associated with cumulative exposure to some antiretroviral agents, together with persistent chronic inflammation, and immune activation associated with HIV infection. Tools are available to calculate an individual's predicted risk of CVD and should be incorporated in the regular follow-up of HIV-infected patients. Targeted interventions to reduce this risk must be recommended, including life-style changes and medical interventions that might include changes in antiretroviral therapy.

Citing Articles

Cardiovascular medication adherence testing in patients living with HIV: A single-centre observational study.

Nazareth J, Adebayo A, Fahad M, Karim H, Pan D, Sze S HIV Med. 2024; 25(12):1330-1339.

PMID: 39315489 PMC: 11608581. DOI: 10.1111/hiv.13715.

Accelerated Neuroimmune Dysfunction in Aged HIV-1-Infected Humanized Mice.

Zhang C, Su H, Waight E, Poluektova L, Gorantla S, Gendelman H Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399364 PMC: 10892358. DOI: 10.3390/ph17020149.

Development trends of immune activation during HIV infection in recent three decades: a bibliometric analysis based on CiteSpace.

Gong K, Lai Y Arch Microbiol. 2023; 205(8):283.

PMID: 37432538 DOI: 10.1007/s00203-023-03624-7.

Resting state network connectivity alterations in HIV: Parallels with aging.

Lew B, McCusker M, ONeill J, Bares S, Wilson T, Doucet G Hum Brain Mapp. 2023; 44(13):4679-4691.

PMID: 37417797 PMC: 10400792. DOI: 10.1002/hbm.26409.

Arterial stiffness is associated with oxidative stress and endothelial activation among persons with treated HIV in Zambia.

Chikopela T, Goma F, Kaluba L, Mutale W, Guure C, Heimburger D South Afr J HIV Med. 2021; 22(1):1298.

PMID: 34858654 PMC: 8603157. DOI: 10.4102/sajhivmed.v22i1.1298.

References

Worm S, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F . Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2009; 201(3):318-30. DOI: 10.1086/649897. View

Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A . HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2007; 199(1):79-86. PMC: 2518204. DOI: 10.1016/j.atherosclerosis.2007.10.018. View

Wohl D, Cohen C, Gallant J, Mills A, Sax P, DeJesus E . A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013; 65(3):e118-20. DOI: 10.1097/QAI.0000000000000057. View

Martin A, Bloch M, Amin J, Baker D, Cooper D, Emery S . Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009; 49(10):1591-601. DOI: 10.1086/644769. View

Rockstroh J, DeJesus E, Lennox J, Yazdanpanah Y, Saag M, Wan H . Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013; 63(1):77-85. DOI: 10.1097/QAI.0b013e31828ace69. View

Martinez E, DAlbuquerque P, Perez I, Pich J, Gatell J . Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res Hum Retroviruses. 2012; 29(2):235-41. PMC: 3552169. DOI: 10.1089/AID.2012.0150. View

Bedimo R, Westfall A, Drechsler H, Vidiella G, Tebas P . Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011; 53(1):84-91. DOI: 10.1093/cid/cir269. View

Abd-Elmoniem K, Unsal A, Eshera S, Matta J, Muldoon N, McAreavey D . Increased coronary vessel wall thickness in HIV-infected young adults. Clin Infect Dis. 2014; 59(12):1779-86. PMC: 4274345. DOI: 10.1093/cid/ciu672. View

Freiberg M, Chang C, Kuller L, Skanderson M, Lowy E, Kraemer K . HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173(8):614-22. PMC: 4766798. DOI: 10.1001/jamainternmed.2013.3728. View

10.

Currier J, Taylor A, Boyd F, Dezii C, Kawabata H, Burtcel B . Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003; 33(4):506-12. DOI: 10.1097/00126334-200308010-00012. View

11.

Crane H, Van Rompaey S, Kitahata M . Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006; 20(7):1019-26. DOI: 10.1097/01.aids.0000222074.45372.00. View

12.

Friis-Moller N, Worm S . Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools?. Clin Infect Dis. 2007; 45(8):1082-4. DOI: 10.1086/521936. View

13.

Grunfeld C, Delaney J, Wanke C, Currier J, Scherzer R, Biggs M . Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009; 23(14):1841-9. PMC: 3156613. DOI: 10.1097/QAD.0b013e32832d3b85. View

14.

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

15.

Triant V, Regan S, Lee H, Sax P, Meigs J, Grinspoon S . Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010; 55(5):615-9. PMC: 3036774. DOI: 10.1097/QAI.0b013e3181f4b752. View

16.

Bozzette S, Ake C, Tam H, Phippard A, Cohen D, Scharfstein D . Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008; 47(3):338-41. DOI: 10.1097/QAI.0b013e31815e7251. View

17.

Chanthong P, Lapphra K, Saihongthong S, Sricharoenchai S, Wittawatmongkol O, Phongsamart W . Echocardiography and carotid intima-media thickness among asymptomatic HIV-infected adolescents in Thailand. AIDS. 2014; 28(14):2071-9. PMC: 4424197. DOI: 10.1097/QAD.0000000000000376. View

18.

Post F, Campbell L . Abacavir and increased risk of myocardial infarction. Lancet. 2008; 372(9641):803. DOI: 10.1016/S0140-6736(08)61330-6. View

19.

Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807. PMC: 4569751. DOI: 10.1056/NEJMoa1506816. View

20.

Obel N, Farkas D, Kronborg G, Larsen C, Pedersen G, Riis A . Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2009; 11(2):130-6. DOI: 10.1111/j.1468-1293.2009.00751.x. View